Abstract
Sinistral portal hypertension (SPH) is an uncommon condition secondary to stenosis of the splenic vein. The most common causes are chronic pancreatitis and pancreatic cancer. This localized hypertension can lead to the development of isolated gastric varices (IGV) in non-cirrhotic patients and potentially life-threatening upper gastrointestinal bleeding. We report a case of pancreatic cancer causing left-sided portal hypertension (LSPH) and isolated gastric varices bleeding. Pancreatic cancer is one of the leading causes of cancer-related death globally. Symptoms are non-specific, and there are no routine screening tests; therefore, the disease tends to be diagnosed in advanced stages. A high suspicion index and systematic diagnosis approach are needed, including inflammatory, infiltrative, and oncological causes, to establish a proper diagnosis.
Keywords: case report, gastric varices, left-sided portal hypertension, pancreatic cancer, sinistral portal hypertension
Introduction
Sinistral portal hypertension (SPH), also known as left-sided portal hypertension (LSPH), segmental, regional, or splenoportal hypertension, is a rare clinical syndrome resulting from the obstruction or stenosis of the splenic vein [1]. The most common underlying causes are pancreatic diseases, including chronic pancreatitis, pancreatic pseudocysts, and pancreatic neoplasms [2]. This condition can lead to the formation of isolated gastric varices (IGV) and upper gastrointestinal bleeding in non-cirrhotic patients [3]. IGV are uncommon, accounting for only 4.7% of all gastric varices in patients with portal hypertension [4]. IGV are classified endoscopically using Sarin's classification, which is based on the varix's anatomical location [5]. IGV type 1 (IGV1) are located in the fundus, and IGV type 2 are distal gastric varices or those found in other sporadic locations [6]. We present a case report of SPH presenting as the initial manifestation of a pancreatic neoplasm. This case report has been reported in line with the CARE checklist [7].
Case presentation
A previously healthy 48-year-old man presented to the emergency department complaining of epigastric abdominal pain, hematemesis, and occasional melena. On admission, he exhibited hypovolemia, tachycardia, and pale oral mucosa. Notably, physical examination showed no external stigmata of chronic liver disease. Initial management for presumed upper gastrointestinal bleeding was instituted, including intravenous fluid resuscitation, analgesics, and proton pump inhibitors (PPIs). At this stage, differential diagnoses included peptic ulcer disease, Mallory-Weiss tear, and variceal bleeding. A comprehensive diagnostic workup was ordered, comprising a complete blood count (CBC), renal function tests, hepatobiliary profile, and abdominal ultrasound (Table 1). An urgent esophagogastroduodenoscopy (EGD) was performed on the next day, identifying isolated gastric varices type 1 (IGV1) as the source of the hemorrhage (Figure 1A).
Table 1. Laboratory data at admission.
AST: aspartate aminotransferase, ALT: alanine aminotransferase, aPTT: activated partial thromboplastin time, INR: international normalized ratio
| Parameter | Patient value | Reference range |
| Hemoglobin (gr/L) | 10.1 | 11.4-14.7 |
| Mean corpuscular volume (fL) | 85.9 | 80-100 |
| Hematocrit (%) | 30.5 | 36.9-54.3 |
| Red cell distribution width (%) | 12.1 | 12-16 |
| White blood cells (cells/μL) | 7,840 | 3,500-13,500 |
| Neutrophils (cells/μL) | 5,820 | 2,500-8,000 |
| Eosinophils (cells/μL) | 0.09 | 0-330 |
| Lymphocytes (cells/μL) | 1,400 | 1,000-4,800 |
| Platelet count (cells/μL) | 147,000 | 150,000-450,000 |
| Creatinine (mg/dL) | 0.99 | 1.1 |
| Blood urea nitrogen (mg/dL) | 17.67 | 6-20 |
| AST (UI/L) | 14.4 | 5-34 |
| ALT (UI/L) | 11.6 | 0-55 |
| Total bilirubin (mg/dL) | 0.30 | 0.1-1 |
| Direct bilirubin (mg/dL) | 0.13 | 0.1-0.3 |
| Indirect bilirubin (mg/dL) | 0.17 | 0.2-0.7 |
| Alkaline phosphatase (UI/L) | 58.50 | 50-116 |
| Amylase (UI/L) | 38.9 | 28-100 |
| Prothrombin time (seconds) | 11.4 | 9.9-11.8 |
| aPTT (seconds) | 23.1 | 25-31.3 |
| INR | 1.08 | 0-1.1 |
Figure 1. Multimodal imaging findings.
(A) EGD: arrows showing IGV1. (B) Angiography demonstrating a large gastrorenal shunt (outflow) directed toward the left renal vein. (C) Abdominal enhanced CT scan in portal venous phase: arrows showing dilated portal vein and splenomegaly. (D) Abdominal enhanced CT: arrow showing a hypodense pancreatic lesion.
EGD: esophagogastroduodenoscopy, IGV1: isolated gastric varices type 1, CT: computed tomography
Initial investigation via abdominal ultrasound yielded conflicting results; it reported a patent portal vein with normal hepatopetal flow and a spleen of normal size, effectively ruling out typical signs of generalized portal hypertension. However, given the critical endoscopic finding of IGV1 standing in stark contrast to the unremarkable ultrasound, the case was discussed with the interventional radiology team. An abdominal computed tomography (CT) angiography was requested, revealing portal hypertension with a large gastrorenal shunt that was successfully embolized without complications (Figure 1B).
Despite effective control of the acute bleeding, a clear etiology for the portal hypertension remained unknown after the initial exhaustive workup (Figure 1C). Consequently, the interdisciplinary team proceeded with advanced imaging. A contrast-enhanced abdominal CT radically shifted the diagnostic focus and identified a primary hyperdense mass involving the body and tail of the pancreas, with retroperitoneal lymphadenopathy (Figure 1D). This finding was accompanied by abnormally high CA 19-9 levels (926 UI/mL). The abdominal CT also revealed signs of diffuse liver cirrhosis with associated cysts and nodules.
Before confirming the pancreatic etiology, the causes of chronic liver disease were ruled out. Viral hepatitis serologies, autoimmune profiles, and workup for Wilson's disease returned negative results (Table 2). Additional testing, notably a pancreatic biopsy, ultimately revealed pancreatic adenocarcinoma. The patient is currently undergoing chemotherapy and shows good clinical progress.
Table 2. Further laboratory testing.
ANA: antinuclear antibody, ANCA: antineutrophil cytoplasmic antibody, ASMA: anti-smooth-muscle antibody
| Parameter | Patient value | Reference range |
| Ceruloplasmin (mg/dL) | 10 | 20-40 |
| ANA | 2:20 | <1:80 |
| ANCA | Negative | Negative |
| ASMA (U) | Negative | >30 U |
| Reticulocyte count (%) | 2.9 | 0.88-2.37 |
| Peripheral blood smear | Hypochromia (+), mild anisocytosis microcytes (+), macrocytes (+), ovalocytes (+) | Normal morphology |
| Haptoglobin (mg/dL) | 173 | 14-268 |
| Direct Coombs test | Negative | Negative |
| Transferrin saturation (%) | 16 | 20-50 |
| Serum iron (µg/dL) | 34 | 65-175 |
| Ferritin (ng/mL) | 35 | 21.81-274.66 |
| 24-hour urinary copper (ug/24 hours) | 14 | 3-50 |
| Vitamin B12 (pg/mL) | 879 | 187-883 |
| CA 19-9 (U/mL) | 926 | 0-37 |
Discussion
Pancreatic cancer is one of the leading causes of cancer-related death globally. It currently ranks as the fifth leading cause of cancer death in the United Kingdom and is projected to climb to the third leading cause of death by 2030 in the United States [8]. The estimated annual incidence of pancreatic cancer in Colombia is approximately 2,812 new cases, representing about 2.4% of the total cancer burden [9]. The clinical course is often challenging because the disease remains asymptomatic until advanced stages. When symptoms emerge, they are usually non-specific, presenting as loss of appetite and changes in bowel habits [10]. Because effective population-level screening methods are lacking, the disease tends to be diagnosed in advanced stages [11].
Pancreatic cancer is a key contributor to SPH [12]. While SPH is a rare condition, accounting for less than 5% of all gastric varices in portal hypertension patients, pancreatic neoplasms, including malignant (pancreatic adenocarcinoma) and benign lesions (pancreatic cyst), are the second most common cause of splenic vein obstruction [13]. A registry of 209 cases of splenic vein obstruction found that pancreatic neoplasm was responsible for approximately 18% of cases, surpassed only by pancreatitis (65%) [14].
IGV1 secondary to splenic vein compression results from a distinct hemodynamic mechanism. When the splenic vein is obstructed, the normal venous outflow from the spleen is impeded, leading to retrograde flow through the short gastric veins [15]. These veins, which connect the splenic hilum to the greater curvature of the stomach, become engorged, forming the fundal varices observed endoscopically [16]. To bypass the obstruction, the high-pressure blood flow seeks a systemic escape route, draining from the varices into the inferior phrenic vein or directly creating a gastrorenal shunt, as was clearly visualized in our patient's angiography (Figure 2) [17].
Figure 2. Schematic diagram showing the pathophysiology of LSPH.
Splenic vein occlusion leads to splenic venous hypertension, which results in the diversion of flow through the SGV, PGV, and GEV. Splenofugal flow in PGV and SGV forms gastric fundal varices and drains into the PV via LGV. GEV also drains splenic venous flow to PV.
LSPH: left-sided portal hypertension, SGV: short gastric vein, PGV: posterior gastric vein, GEV: gastroepiploic vein, PV: portal vein, LGV: left gastric vein, SV: splenic vein
Adapted with permission from Patel et al. [17]
Management of SPH focuses primarily on treating the underlying cause. For definitive treatment of SPH, both open surgical and endovascular procedures have been established. However, in patients who are poor surgical candidates or require immediate stabilization, splenic artery embolization is an effective alternative. It is important to note that transjugular intrahepatic portosystemic shunt (TIPS) is generally not indicated in SPH cases. TIPS leads to direct decompression of the portal pressure (right-sided portal hypertension), which is usually not elevated in cases of SPH (left-sided portal hypertension).
Conclusions
The identification of IGV1 as the source of upper gastrointestinal bleeding in a patient without external stigmata of chronic liver disease poses a significant diagnostic challenge. The differential diagnosis is broad, encompassing inflammatory, infiltrative, and oncological causes. Therefore, a multidisciplinary and systematic approach is crucial, initially evaluating the most common etiologies before proceeding in a stepwise manner toward more complex diagnoses.
Acknowledgments
We would like to acknowledge the nursing staff of Comfamiliar Clinic.
Disclosures
Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study.
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:
Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.
Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.
Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Author Contributions
Concept and design: Sergio David Angulo, Julian Toro, Jesús Hinestroza, Isabel Sánchez, David Cataño, Leisly T. Oviedo Gomez
Acquisition, analysis, or interpretation of data: Sergio David Angulo, Julian Toro, Jesús Hinestroza, Isabel Sánchez, David Cataño, Leisly T. Oviedo Gomez
Drafting of the manuscript: Sergio David Angulo, Julian Toro, Jesús Hinestroza, Isabel Sánchez, David Cataño, Leisly T. Oviedo Gomez
Critical review of the manuscript for important intellectual content: Sergio David Angulo, Julian Toro, Jesús Hinestroza, Isabel Sánchez, David Cataño, Leisly T. Oviedo Gomez
Supervision: Sergio David Angulo, Julian Toro, Jesús Hinestroza, Isabel Sánchez, David Cataño, Leisly T. Oviedo Gomez
References
- 1.Left-sided portal hypertension: a sinister entity. Fernandes A, Almeida N, Ferreira AM, et al. GE Port J Gastroenterol. 2015;22:234–239. doi: 10.1016/j.jpge.2015.09.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Left-sided portal hypertension: update and proposition of management algorithm. Mayer P, Venkatasamy A, Baumert TF, Habersetzer F, Pessaux P, Saviano A, Felli E. J Visc Surg. 2024;161:21–32. doi: 10.1016/j.jviscsurg.2023.11.005. [DOI] [PubMed] [Google Scholar]
- 3.Left portal hypertension with bleeding from gastric varices as a presentation of hypernephroma (Article in Spanish) Seijo J, Loarte DV, Martínez M, et al. https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-71992004000600006 An Med Interna (Madrid) 2004;21:288–290. [Google Scholar]
- 4.Bleeding isolated gastric varices as a rare presentation of pancreatic neuroendocrine tumor: case report and literature review. Sompalli S, Faiek S, Mallari M, Camarena J 3rd. Cureus. 2020;12:0. doi: 10.7759/cureus.9670. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Isolated gastric varices: prevalence, clinical relevance and natural history. Sarin SK, Jain AK, Lamba GS, Gupta R, Chowdhary A. Dig Surg. 2003;20:42–47. doi: 10.1159/000068865. [DOI] [PubMed] [Google Scholar]
- 6.Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. Sarin SK, Lahoti D, Saxena SP, Murthy NS, Makwana UK. Hepatology. 1992;16:1343–1349. doi: 10.1002/hep.1840160607. [DOI] [PubMed] [Google Scholar]
- 7.The CARE guidelines: consensus-based clinical case reporting guideline development. Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D. BMJ Case Rep. 2013;2013 doi: 10.1186/1752-1947-7-223. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Cancer Research UK: Pancreatic cancer statistics. [ Mar; 2025 ]. 2025. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/pancreatic-cancer https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/pancreatic-cancer
- 9.International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: a joinpoint regression analysis. Ilic I, Ilic M. World J Gastroenterol. 2022;28:4698–4715. doi: 10.3748/wjg.v28.i32.4698. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Global Cancer Observatory: Cancer Today. [ Oct; 2025 ]. 2024. https://gco.iarc.who.int/today https://gco.iarc.who.int/today
- 11.Pancreatic cancer: a review. Park W, Chawla A, O'Reilly EM. JAMA. 2021;326:851–862. doi: 10.1001/jama.2021.13027. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Gastrointestinal bleeding due to pancreatic disease-related portal hypertension. Zheng K, Guo X, Feng J, et al. Gastroenterol Res Pract. 2020;2020:3825186. doi: 10.1155/2020/3825186. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Sinistral portal hypertension: clinical features and surgical treatment of chronic splenic vein occlusion. Wang L, Liu GJ, Chen YX, Dong HP, Wang LX. Med Princ Pract. 2012;21:20–23. doi: 10.1159/000329888. [DOI] [PubMed] [Google Scholar]
- 14.How to approach a patient with gastric varices. Maydeo A, Patil G. Gastroenterology. 2022;162:689–695. doi: 10.1053/j.gastro.2021.12.277. [DOI] [PubMed] [Google Scholar]
- 15.Bleeding from isolated gastric varices as complication of a mucinous cystic neoplasm of the pancreas: a case report. Lupascu-Ursulescu C, Trofin AM, Zabara M, et al. Medicine (Baltimore) 2017;96:0. doi: 10.1097/MD.0000000000008775. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Pancreatic mass leading to left-sided portal hypertension, causing bleeding from isolated gastric varices. Thrainsdottir H, Petursdottir V, Blöndal S, Björnsson ES. Case Rep Gastrointest Med. 2014;2014:956490. doi: 10.1155/2014/956490. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Left-sided portal hypertension: what an interventional radiologist can offer? Patel RK, Tripathy T, Chandel K, et al. Eur Radiol. 2025;35:2530–2542. doi: 10.1007/s00330-024-11196-3. [DOI] [PubMed] [Google Scholar]


